{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:01:55Z","timestamp":1792879315369,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.idnow.2025.105242","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:11:22Z","timestamp":1766131882000},"page":"105242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Standard- versus high-dose tigecycline in pneumonia due to carbapenem-resistant Acinetobacter baumannii: A propensity score\u2013matched retrospective study"],"prefix":"10.1016","volume":"56","author":[{"given":"\u00d6zge","family":"\u00d6zgen-Top","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"Aysert-Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Tekin-Ta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyma","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8514-4753","authenticated-orcid":false,"given":"Emincan","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3882-5860","authenticated-orcid":false,"given":"Fatma Zehra","family":"\u00d6zcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Ay\u00e7a","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Dizbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2025.105242_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.823684","article-title":"Global Threat of Carbapenem-Resistant Gram-negative Bacteria","volume":"12","author":"Jean","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.idnow.2025.105242_b0010","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024:ciae403. doi: 10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"10.1016\/j.idnow.2025.105242_b0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12941-017-0199-8","article-title":"The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.idnow.2025.105242_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2014.01.006","article-title":"Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections","volume":"44","author":"Falagas","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2025.105242_b0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2015.08.009","article-title":"Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs","volume":"39","author":"Shen","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.idnow.2025.105242_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106487","article-title":"Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia","volume":"59","author":"Dimopoulos","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.idnow.2025.105242_b0035","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/jcpt.13823","article-title":"Pharmacokinetic\/pharmacodynamic analysis of high-dose tigecycline, by Monte Carlo simulation, in plasma and sputum of patients with hospital-acquired pneumonia","volume":"47","author":"Qin","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.idnow.2025.105242_b0040","doi-asserted-by":"crossref","first-page":"e9961","DOI":"10.1097\/MD.0000000000009961","article-title":"High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study","volume":"97","author":"Geng","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.idnow.2025.105242_b0045","article-title":"Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.idnow.2025.105242_b0050","unstructured":"National Cancer Institute [Internet]. 2017. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. [cited September 8, 2025]. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-8x11.pdf."},{"key":"10.1016\/j.idnow.2025.105242_b0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Ventilator-associated, and Healthcare-associated Pneumonia","volume":"171","author":"Guidelines for the Management of Adults with Hospital-acquired","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.idnow.2025.105242_b0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000445425","article-title":"Efficacy and Safety of Tigecycline for patients with Hospital-acquired Pneumonia","volume":"61","author":"Xu","year":"2016","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2025.105242_b0065","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2147\/IDR.S249352","article-title":"High-Dose Tigecycline in elderly patients with Pneumonia due to Multidrug-Resistant Acinetobacter baumannii in Intensive Care Unit","volume":"13","author":"Bai","year":"2020","journal-title":"IDR"},{"key":"10.1016\/j.idnow.2025.105242_b0070","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12879-023-08815-7","article-title":"Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units","volume":"23","author":"Bai","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.idnow.2025.105242_b0075","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: a Systematic Review and Meta-Analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.idnow.2025.105242_b0080","doi-asserted-by":"crossref","DOI":"10.5114\/aoms\/165833","article-title":"Systematic evaluation and Meta-analysis of the efficacy and safety of different doses of tigecycline in ventilator-associated pneumonia caused by multiple resistant bacteria","author":"Feng","year":"2023","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.idnow.2025.105242_b0085","article-title":"Evaluating tigecycline dosing for hospital-acquired pneumonia patients: insights from physiologically-based pharmacokinetic modeling of lung exposure","volume":"e00004","author":"Zhang","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105242_b0090","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.asjsur.2022.06.193","article-title":"Efficacy of double-dose tigecycline in the treatment of ventilator-associated pneumonia: a meta-analysis","volume":"46","author":"Sun","year":"2023","journal-title":"Asian J Surg"},{"key":"10.1016\/j.idnow.2025.105242_b0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jiph.2023.01.004","article-title":"A two-year retrospective study of multidrug-resistant Acinetobacter baumannii respiratory infections in critically Ill patients: Clinical and microbiological findings","volume":"16","author":"Hafiz","year":"2023","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.idnow.2025.105242_b0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40560-015-0077-4","article-title":"Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"3","author":"Inchai","year":"2015","journal-title":"J Intensive Care"},{"key":"10.1016\/j.idnow.2025.105242_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.761167","article-title":"Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury among patients in China: a 3-year Retrospective Study as Assessed by the Updated RUCAM","volume":"12","author":"Shi","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.idnow.2025.105242_b0110","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/jcph.2099","article-title":"Risk Factors for Tigecycline\u2010Associated Hepatotoxicity in patients in the Intensive Care units of 2 Tertiary hospitals: a Retrospective Study","volume":"62","author":"Jiang","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.idnow.2025.105242_b0115","article-title":"Influence of tigecycline on liver function in adult patients in the intensive care unit","author":"Song","year":"2021","journal-title":"Research Square [Preprint]"},{"key":"10.1016\/j.idnow.2025.105242_b0120","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/0016-5085(94)90830-3","article-title":"Tetracycline-induced bile duct paucity and prolonged cholestasis","volume":"107","author":"Hunt","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idnow.2025.105242_b0125","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1248\/bpb.35.967","article-title":"Adverse Event Profile of Tigecycline: Data Mining of the Public Version of the U.S. Food and Drug Administration adverse Event Reporting System","volume":"35","author":"Kadoyama","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.idnow.2025.105242_b0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijid.2022.04.024","article-title":"Prevalence and risk factors of tigecycline-induced liver injury: a multicenter retrospective study","volume":"120","author":"Yu","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.idnow.2025.105242_b0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","article-title":"Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database","volume":"20","author":"Guo","year":"2022","journal-title":"Thrombosis J"},{"key":"10.1016\/j.idnow.2025.105242_b0140","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s11096-020-00974-w","article-title":"Tigecycline-induced coagulopathy: a literature review","volume":"42","author":"Hakeam","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.idnow.2025.105242_b0145","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/1120009X.2022.2153315","article-title":"Tigecycline treatment causes a decrease in peripheral blood platelet","volume":"35","author":"Huang","year":"2023","journal-title":"J Chemother"},{"key":"10.1016\/j.idnow.2025.105242_b0150","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/14740338.2024.2309225","article-title":"Hematological adverse events associated with anti-MRSA agents: a real-world analysis based on FAERS","volume":"23","author":"Yu","year":"2024","journal-title":"Expert Opin Drug Saf"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925002210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925002210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:28:24Z","timestamp":1782941304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991925002210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666991925002210"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105242","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standard- versus high-dose tigecycline in pneumonia due to carbapenem-resistant Acinetobacter baumannii: A propensity score\u2013matched retrospective study","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105242"}}